Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary\r\nartery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosisbased\r\ndisorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin\r\nwas not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed\r\nantithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few\r\ndecades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However,\r\ngiven some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and\r\ncardiovascular disorders and is expected to do so for years to come.
Loading....